| Autor: |
Recht, Lawrence, Glantz, Michael, Meitner, Patricia, Glantz, Lisa, Akerley, Wallace, Wahlberg, Lars, Saris, Stephen, Cole, Bernard |
| Zdroj: |
Journal of Neuro-Oncology; Feb1998, Vol. 36 Issue 3, p209-217, 9p |
| Abstrakt: |
To individually tailor chemotherapy for patients with malignant gliomas according to tumor chemosensitivity, a rapid assay system which can be performed with a high success rate is needed. The fluorescent cytoprint assay (FCA) can assess multiple chemotherapeutic agents using small (≈ 500 cells) tumor aggregates very quickly (≌ 1 wk). Tissue samples from 51 patients with malignant gliomas obtained either at time of initial diagnosis (n=34) or at recurrence were assayed using this method. The assay success rate approached 90% in those culture samples which were histologically verified as tumor. A meaningful number of agents could be tested both on samples obtained by stereotactic biopsy (median, 5) and on specimens from more extensive resections (median, 6). One hundred ninety-three FCAs were performed on a samples obtained from 36 patients. In only twenty six assays (14%) was an agent deemed sensitive (> 90% cell kill) to a chemotherapeutic agent. Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (# samples sensitive/total tested against agent) of 64% (95% CI, 36.6–77.9%) was noted. This rate was significantly higher than with any other agent tested (p=0.012, two sided McNemar's test) and was not affected by age, histology or disease status. We conclude that: (1) the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and (ii) malignant gliomas may be particularly sensitive to 4-HC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink